Nonalcoholic fatty liver disease-evidence for a thrombophilic state?

Margaret Spinosa, Jonathan G. Stine

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Nonalcoholic fatty liver disease is the leading cause of liver disease worldwide. It has expansive extra-hepatic morbidity and mortality including increased rates of both cardiovascular disease and venous thromboem-bolism. Derangements in primary, secondary and tertiary hemostasis are found in nonalcoholic fatty liver disease independent of those ascribed to end-stage liver disease. The abnormalities across all stages of hemostasis explain the increased rates of clinically relevant thrombotic events, including pulmonary embolism, deep vein thrombosis and portal vein thrombosis, which on an epidemiologic basis appears to be independent of obesity and other traditional venous thromboembolic risk factors. However, given the complex interaction between obesity, body composition and nonalcoholic fatty liver disease and the potential for exercise to benefit all three, more research is needed to further define the role of each in contributing to the prohemostatic state of nonalcoholic fatty liver disease in order to improve patient oriented outcomes.

Original languageEnglish (US)
Pages (from-to)1036-1044
Number of pages9
JournalCurrent Pharmaceutical Design
Issue number10
StatePublished - 2020

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Nonalcoholic fatty liver disease-evidence for a thrombophilic state?'. Together they form a unique fingerprint.

Cite this